FY2026 Earnings Estimate for PolyPid Issued By HC Wainwright

PolyPid Ltd. (NASDAQ:PYPD) – Investment analysts at HC Wainwright boosted their FY2026 earnings per share estimates for shares of PolyPid in a research note issued on Monday, June 9th. HC Wainwright analyst B. Folkes now expects that the company will post earnings of ($1.09) per share for the year, up from their previous forecast of ($1.10). HC Wainwright currently has a “Buy” rating and a $13.00 target price on the stock. The consensus estimate for PolyPid’s current full-year earnings is ($1.79) per share. HC Wainwright also issued estimates for PolyPid’s FY2027 earnings at ($0.51) EPS, FY2028 earnings at $0.21 EPS and FY2029 earnings at $1.62 EPS.

Separately, Roth Capital started coverage on PolyPid in a report on Thursday, June 5th. They set a “buy” rating and a $9.00 price target for the company. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $11.25.

PolyPid Stock Down 0.6%

Shares of PolyPid stock opened at $3.41 on Thursday. The firm has a market cap of $34.75 million, a price-to-earnings ratio of -0.69 and a beta of 1.25. The company has a debt-to-equity ratio of 0.08, a current ratio of 1.31 and a quick ratio of 1.00. PolyPid has a 52-week low of $2.30 and a 52-week high of $4.49. The stock has a 50-day simple moving average of $2.82 and a 200-day simple moving average of $2.92.

PolyPid (NASDAQ:PYPD) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.80) by $0.10.

Institutional Investors Weigh In On PolyPid

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. AIGH Capital Management LLC lifted its holdings in PolyPid by 13.6% in the 1st quarter. AIGH Capital Management LLC now owns 940,381 shares of the company’s stock worth $2,548,000 after purchasing an additional 112,514 shares during the last quarter. J. Goldman & Co LP acquired a new stake in PolyPid in the 4th quarter worth approximately $391,000. Finally, Rosalind Advisors Inc. lifted its holdings in PolyPid by 49.9% in the 4th quarter. Rosalind Advisors Inc. now owns 1,018,021 shares of the company’s stock worth $3,095,000 after purchasing an additional 338,853 shares during the last quarter. 26.47% of the stock is currently owned by institutional investors and hedge funds.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.